<li>alvimopan<p>atorvastatin will increase the level or effect of alvimopan by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>armodafinil<p>atorvastatin will increase the level or effect of armodafinil by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>coenzyme q10<p>atorvastatin decreases levels of coenzyme q10 by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>colestipol<p>colestipol decreases levels of atorvastatin by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>fexofenadine<p>atorvastatin will increase the level or effect of fexofenadine by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>fluvoxamine<p>fluvoxamine will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>isradipine<p>isradipine decreases levels of atorvastatin by unknown mechanism. Minor/Significance Unknown.</p></li><li>loratadine<p>atorvastatin will increase the level or effect of loratadine by  P-glycoprotein (MDR1) efflux transporter. Minor/Significance Unknown.</p></li><li>orlistat<p>orlistat increases effects of atorvastatin by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>ruxolitinib<p>atorvastatin will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown.</p></li><li>trazodone<p>trazodone increases levels of atorvastatin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li>